Inclusion Criteria:
* Men and women aged 18 to 70 years.
* Self-perceived occasional telogen effluvium, with a count of 100 or more shed hairs in the standardized wash and combing test, confirmed at the screening visit (Visit 0), of recent onset (less than 6 months) and attributable to factors such as stress, nutritional deficiency, pollution, or seasonality.
* Good general health, in the investigator's judgment, with no relevant uncontrolled systemic disease.
* Availability and willingness to attend the three study visits and comply with study procedures over a 90-day period.
* Agreement to receive study-related communications electronically (email and/or SMS), where expressly authorized.
* Ability to understand the study and provide written informed consent.
Exclusion Criteria:
* Refusal to provide informed consent to participate in the study.
* Inability to understand the study language.
* Pregnancy or breastfeeding.
* Established androgenetic alopecia (Hamilton-Norwood classification or other pattern hair loss disorders) or other forms of alopecia (alopecia areata, scarring alopecia, trichotillomania, or others) diagnosed or suspected by the investigator.
* Use of specific pharmacological or cosmetic treatments for hair loss (minoxidil, finasteride, topical or systemic corticosteroids, other dietary supplements, or hair lotions) within the 3 months prior to enrollment.
* Uncontrolled endocrine disease (e.g., thyroid disorders), diagnosed severe nutritional deficiency, untreated anemia, or a recent history (\< 6 months) of severe febrile illness, major surgery, or childbirth.
* Active scalp dermatological conditions (psoriasis, moderate-to-severe seborrheic dermatitis, fungal or bacterial infections) that may interfere with clinical assessment or instrumental evaluation techniques.
* Any disease, treatment, or characteristic that, in the investigator's opinion, may preclude participation due to unnecessary risk or interference with the study and/or interpretation of the results, particularly:
* Use of aspirin or related compounds, antibiotics, anti-inflammatory drugs, corticosteroids, antidepressants, antihistamines, or immunosuppressive treatments.
* Ongoing allergen desensitization therapy (allergy immunotherapy).
* Presence of dermatological abnormalities in the study area, such as irritation, erythema, scars, pigmentation disorders, numerous freckles, or nevi.
* History of intolerance or allergy to medications or other substances that may pose an unjustified risk.
* Use of a nutricosmetic supplement within the 3 months prior to study initiation or during the entire study period.
* History of intolerance or allergy to cosmetic products of the same type as the investigational product.
* Receipt of a vaccination within the previous month or planned vaccination during the study period.
* Surgical intervention in the study area within the month prior to study initiation or during the study.
* Undergoing aesthetic procedures that may affect the scalp during the study, such as oxidative root hair coloring, perming, Japanese straightening, keratin straightening, or full hair bleaching (color rinses, temporary dyes, highlights, light hairstyling, and salon styling procedures are permitted).
* Combing, washing, or dyeing the hair within the 48 hours preceding a study visit.
* Simultaneous participation in other studies related to the same therapeutic or application area.
* Modification of cosmetic habits in the study area within the 15 days prior to study initiation.
Exposure to intense sunlight or ultraviolet (UV) radiation within the month prior to study enrollment, or anticipated exposure during the study period.
